{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tusamitamab ravtansine","ramucirumab"],["tusamitamab ravtansine","ramucirumab","pembrolizumab"]],"indication":"previously treated CEACAM5-positive metastatic non-squamous NSCLC","name":"CARMEN-LC04","nct_id":"NCT04394624","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=carmen-lc04-nct04394624. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CARMEN-LC04","arms":[{"description":"Ramucirumab will be administered intravenously prior to intravenously adminstration of SAR408701 every two 2 weeks.","label":"Ramucirumab + SAR408701","type":"EXPERIMENTAL"},{"description":"Participants will be treated with tusamitamab ravtansine and ramucirumab and pembrolizumab to assess the tolerability of the combination","label":"Ramucirumab + pembrolizumab +SAR408701","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-10-24","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer Metastatic"],"enrollment":{"count":31,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"SAR408701","otherNames":[],"type":"DRUG"},{"name":"ramucirumab","otherNames":[],"type":"DRUG"},{"name":"pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2025-06-06","lead_sponsor":"Sanofi","official_title":"Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Tusamitamab Ravtansine (SAR408701) Used in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Metastatic, Non-squamous, Non Small-cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-positive Tumors, Previously Treated With Platinum-based Chemotherapy and an Immune Checkpoint Inhibitor","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-03-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Doublet Cohort - Part 1: Number of Participants With Study Drug-Related Dose-Limiting Toxicity (DLT)","timeFrame":"From Cycle 1 Day 1 up to Cycle 2 Day 14, approximately 28 days"},{"measure":"Doublet Cohort - Part 2: Objective Response Rate (ORR)","timeFrame":"Tumor assessments performed at baseline, and every 8 weeks +/-7 days thereafter, approximately 130 weeks"},{"measure":"Triplet Cohort: Number of Participants With Study Drug-Related Dose-Limiting Toxicity","timeFrame":"From Cycle 1 Day 1 up to Cycle 1 Day 21"}],"references":[],"start_date":{"date":"2020-08-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)","url":"https://clinicaltrials.gov/study/NCT04394624"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/carmen-lc04-nct04394624"}